Role of pharmacogenetics on adjuvant chemotherapy-induced neutropenia in Chinese breast cancer patients

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 3, 2013, Pages 419-427

  Tang, Nelson L S ^a,b,c,d   Liao, Chen Di ^a   Wang, Xingyan ^a   Mo, Frankie K F ^a   Chan, Vicky T C ^a   Ng, Rita ^a   Pang, Elizabeth ^a   Suen, Joyce J S ^a   Woo, Jean ^c   Yeo, Winnie ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^b Li Ka Shing Institute of Health Sciences   (Hong Kong)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d KIZ/CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases   (China)

Author keywords

Adjuvant chemotherapy; CYP3A5 gene; Neutropenia; Pharmacogenetics

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DOXORUBICIN; GENOMIC DNA; ANTINEOPLASTIC AGENT; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A;

ADULT; AGED; ALLELE; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CHINESE; COHORT ANALYSIS; CONTROLLED STUDY; CYP3A4 GENE; CYP3A5 GENE; DISEASE SEVERITY; DNA EXTRACTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENE; GENE CLUSTER; GENETIC ASSOCIATION; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HAPLOTYPE; HETEROZYGOTE; HIGH RESOLUTION MELTING ANALYSIS; HIGH RISK POPULATION; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; NR1I2 GENE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; ADJUVANT CHEMOTHERAPY; ADOLESCENT; ASIAN; BREAST TUMOR; CARCINOMA; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; ETHNOLOGY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PHYSIOLOGY; STATISTICS;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; CARCINOMA; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; CYTOCHROME P-450 CYP3A; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; NEUTROPENIA; PHARMACOGENETICS; YOUNG ADULT;

MLCS; MLOWN;

EID: 84876300606     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1345-5     Document Type: Article

References (38)

1. Anglicheau D, Legendre C, Beaune P, Thervet E (2007) Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update. Pharmacogenomics 8(7):835-849
2. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21(2):263-265. doi: 10.1093/bioinformatics/bth457
3. Beith J, Goh B, Yeo W, Sullivan A, Lim S, Zhong S, Rivory L (2002) Interethnic differences in the myelotoxicity of adriamycin/cyclophosphamide (AC) for adjuvant breast cancer. In: Proceedings of American Society of Clinical Oncology Annual Meeting: J Clin Oncol 21:64a, #252
4. Bray J, Sludden J, Griffin MJ, Cole M, Verrill M, Jamieson D, Boddy AV (2010) Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer 102(6):1003-1009
5. Chew HK, Doroshow JH, Frankel P et al (2009) Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer. J Clin Oncol 27(13):2163-2169
6. Du J, Xing Q, Xu L et al (2006) Systematic screening for polymorphisms in the CYP3A4 gene in the Chinese population. Pharmacogenomics 7(6):831-841
7. Fleeman N, Martin Saborido C, Payne K et al (2011) The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review. Health Technol Assess 15(33):1-102
8. Grann VR, Bowman N, Joseph C et al (2008) Neutropenia in 6 ethnic groups from the Caribbean and the U.S. Cancer 113(4):854-860
9. Han HS, Reis IM, Zhao W et al (2011) Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer. Eur J Cancer 47(17):2537-2545
10. Hor SY, Lee SC, Wong CI et al (2008) PXR, CAR and HNF4alpha genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients. Pharmacogenomics J 8(2):139-146
11. Hu YF, He J, Chen GL et al (2005) CYP3A5 3 and CYP3A4 18 single nucleotide polymorphisms in a Chinese population. Clin Chim Acta 353(1-2):187-192
12. Ihunnah CA, Jiang M, Xie W (2011) Nuclear receptor PXR, transcriptional circuits and metabolic relevance. Biochim Biophys Acta 1812(8):956-963
13. Jiang J, Tang NL, Ohlsson C et al (2009) Association of genetic variations in aromatase gene with serum estrogen and estrogen/testosterone ratio in Chinese elderly men. Clin Chim Acta 411(1-2):53-58
14. Jiang J, Tang NL, Ohlsson C et al (2010) Association of SRD5A2 variants and serum androstane-3alpha,17beta-diol glucuronide concentration in Chinese elderly men. Clin Chem 56(11):1742-1749
15. Kim K-P, Ahn J-H, Kim S-B, Jung KH, Yoon DH, Lee JS, Ahn S-H (2012) Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy. Cancer Chemother Pharmacol 69(5):1221-1227. doi: 10.1007/s00280-011-1816-4
16. King BP, Leathart JB, Mutch E, Williams FM, Daly AK (2003) CYP3A5 phenotype-genotype correlations in a British population. Br J Clin Pharmacol 55(6):625-629
17. Kuehl P, Zhang J, Lin Y et al (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27(4):383-391
18. Law C-C, Fu Y-T, Chau K-K, Choy T-S, So P-F, Wong K-H (2007) Toxicity profile and efficacy of oral capecitabine as adjuvant chemotherapy for Chinese patients with Stage III colon cancer. Dis Colon Rectum 50(12):2180-2187
19. Ling WHY, Lee SC (2011) Inter-ethnic differences - how important is it in cancer treatment? Ann Acad Med Singap 40(8):356-361
20. Low SK, Kiyotani K, Mushiroda T, Daigo Y, Nakamura Y, Zembutsu H (2009) Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients. J Hum Genet 54(10):564-571
21. Ma B, Yeo W, Hui P, Ho WM, Johnson PJ (2002) Acute toxicity of adjuvant doxorubicin and cyclophosphamide for early breast cancer - a retrospective review of Chinese patients and comparison with an historic Western series. Radiother Oncol 62(2):185-189
22. Ma BBY, Hui EP, Mok TSK (2010) Population-based differences in treatment outcome following anticancer drug therapies. Lancet Oncol 11(1):75-84
23. Nakajima M, Komagata S, Fujiki Y et al (2007) Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients. Pharmacogenet Genomics 17(6):431-445
24. Phan VH, Moore MM, McLachlan AJ, Piquette-Miller M, Xu H, Clarke SJ (2009) Ethnic differences in drug metabolism and toxicity from chemotherapy. Expert Opin Drug Metab Toxicol 5(3):243-257
25. Phan VH, Tan C, Rittau A, Xu H, McLachlan AJ, Clarke SJ (2011) An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs. Expert Opin Drug Metab Toxicol 7(11):1395-1410
26. Regan MM, Leyland-Jones B, Bouzyk M et al (2012) CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst 104(6):441-451
27. Rizzo R, Spaggiari F, Indelli M, Lelli G, Baricordi OR, Rimessi P, Ferlini A (2010) Association of CYP1B1 with hypersensitivity induced by taxane therapy in breast cancer patients. Breast Cancer Res Treat 124(2):593-598
28. Sandanaraj E, Lal S, Selvarajan V et al (2008) PXR pharmacogenetics: association of haplotypes with hepatic CYP3A4 and ABCB1 messenger RNA expression and doxorubicin clearance in Asian breast cancer patients. Clin Cancer Res 14(21):7116-7126
29. Shih PS, Huang JD (2002) Pharmacokinetics of midazolam and 1′-hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metab Dispos 30(12):1491-1496
30. Sohn KJ, Croxford R, Yates Z, Lucock M, Kim YI (2004) Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst 96(2):134-144
31. Tirona RG (2010) Impact of nuclear receptors CAR, PXR, FXR, and VDR, and their ligands on enzymes and transporters. In: Pang KS, Rodrigues AD, Peter RM (eds) Enzyme- and transporter-based drug-drug interactions, progress and future challenges, 1st edn. Springer, New York, pp 75-105. doi: 10.1007/978-1-4419- 0840-7-4
32. Tsai SM, Lin CY, Wu SH, Hou LA, Ma H, Tsai LY, Hou MF (2009) Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms. Clin Chim Acta 404(2):160-165
33. Wang J, Chuang K, Ahluwalia M et al (2005) High-throughput SNP genotyping by single-tube PCR with Tm-shift primers. Biotechniques 39(6):885-893
34. Wong ALA, Yap HL, Yeo WL et al (2011) Gemcitabine and platinum pathway pharmacogenetics in Asian breast cancer patients. Cancer Genomics Proteomics 8(5):255-259
35. Yao S, Barlow WE, Albain KS et al (2010a) Gene polymorphisms in cyclophosphamide metabolism pathway, treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer. Clin Cancer Res 16(24):6169-6176
36. Yao S, Barlow WE, Albain KS et al (2010b) Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer. Breast Cancer Res Treat 124(2):433-439
37. Yau T, Ng T, Soong I et al (2009) Toxicity of docetaxel plus cyclophosphamide as adjuvant therapy for breast cancer in Chinese patients - the Hong Kong experience. Asia Pac J Clin Oncol 5(2):123-128
38. Zhou Q, Yu X, Shu C et al (2011) Analysis of CYP3A4 genetic polymorphisms in Han Chinese. J Hum Genet 56(6):415-422